Association of stem cell marker CD133 expression with dissemination of glioblastomas
Association of stem cell marker CD133 expression with dissemination of glioblastomas
复制标题
DOI：
10.1007/s10143-010-0239-8
复制
发表时间：
2010-04-01
影响因子：
2.8
通讯作者：
Kayama, Takamasa
中科院分区：
文献类型：
--
作者：
Sato, Atsushi;Sakurada, Kaori;Kayama, Takamasa
胶质母细胞瘤的扩散曾经被认为是罕见的，但现在越来越多地遇到胶质母细胞瘤患者的生存期更长。尽管播散对临床结果有潜在的负面影响，但是，用于预测播散风险的分子标志物仍然不明确。在这项研究中，我们测试了干细胞标志物CD 133的表达和26例胶质母细胞瘤（16例播散和10例无播散）的播散风险之间的关联。通过肿瘤标本的蛋白质印迹分析检测CD 133的蛋白质表达，并通过光密度测定法定量CD 133表达水平，并将其标准化为β-肌动蛋白。结果表明，CD 133表达水平在有播散的胶质母细胞瘤中（平均10.3，范围0.20-27.8）显著高于无播散的胶质母细胞瘤（平均1.18，范围0.07-3.58）。结果表明，CD 133可能是胶质母细胞瘤扩散的分子预测因子，并且还产生了一个有趣的想法，即CD 133阳性癌症干细胞可能与扩散性病变的发生有关。
Dissemination of glioblastoma was once considered rare but is now increasingly encountered with longer survival of glioblastoma patients. Despite the potential negative impact of dissemination on clinical outcome, however, molecular markers useful for prediction of dissemination risk still remains ill defined. We tested in this study for an association between the expression of stem cell marker CD133 and the risk of dissemination in 26 cases of glioblastoma (16 with dissemination and 10 without dissemination). The protein expression of CD133 was examined by western blot analysis of tumor specimens, and the CD133 expression levels were quantified by densitometry and normalized to beta-actin. The results indicated that CD133 expression levels are significantly higher in glioblastomas with dissemination (mean 10.3, range 0.20-27.8) than in those without (mean 1.18, range 0.07-3.58). The results suggest that CD133 could be a molecular predictor of glioblastoma dissemination, and also give rise to an intriguing idea that CD133-positive cancer stem cells may be implicated in the initiation of disseminated lesions.